Meeting
2020 ASCO Virtual Scientific Program
Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials.
Authors
Smith Giri
University of Alabama at Birmingham, Birmingham, AL
Smith Giri , Alyssa Grimshaw , Susan Bal , Kelly Nicole Godby , Prakash Kharel , Benjamin Djulbegovic , Saad Zafar Usmani , Thierry Facon , Philippe Moreau , Meletios A. Dimopoulos , Maria-Victoria Mateos , Luciano J. Costa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8540)
DOI
10.1200/JCO.2020.38.15_suppl.8540
Abstract #
8540
Poster Bd #
440
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.
First Author: Meletios A. Dimopoulos
Poster
2018 ASCO Annual Meeting
Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.
First Author: S.Vincent Rajkumar
Poster
2016 ASCO Annual Meeting
Efficacy and safety of triplet versus doublet salvage therapies among relapsed myeloma patients: Meta-analysis of phase 3 randomized controlled trials.
First Author: Ajay K. Nooka
Poster
2023 ASCO Annual Meeting
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
First Author: Sebastian Grosicki